Zhejiang Weixin Biological Pharmaceutical

Zhejiang Weixin Biological Pharmaceutical, a subsidiary of AIM Vaccine Co., Ltd., is a prominent Chinese biotechnology company specializing in the development and manufacture of human vaccines. Founded in 2002 and based in Ninghai, Zhejiang, the company maintains a diverse portfolio of commercialized products, including vaccines for mumps, hemorrhagic fever with renal syndrome (HFRS), and meningococcal disease. Its advanced R&D pipeline features innovative candidates such as a bivalent mRNA COVID-19 vaccine in Phase 3 trials and a novel bacterial complex vaccine (Neo-BCV) being evaluated for oncology indications like lung cancer. The company operates large-scale GMP-certified manufacturing facilities and is a key contributor to China's national immunization programs. Through its integration with the AIM Vaccine group, it leverages advanced technology platforms in mRNA and cell culture to address emerging global health challenges.